Literature DB >> 7730605

Heavy chain V gene-specific elimination of B cells during the pre-B cell to B cell transition.

D J Decker1, G H Kline, T A Hayden, S N Zaharevitz, N R Klinman.   

Abstract

As developing B cells acquire their surface Ig (sIg) receptors, they become highly susceptible to sIg-mediated negative selection, a process best exemplified by tolerance induction. Recent studies with sIg transgenic mice have suggested that B cells may become inactivated by tolerogens only after a developmental stage wherein they express low levels of sIgM and during the course of up-regulating their expression of sIgM. To determine whether inactivation of B cells of conventional mice occurs at this or other maturational stages, we have analyzed the ratio of productive vs nonproductive rearrangements of VH81X gene segments in developmental subsets of adult bone marrow cells. Earlier studies had demonstrated that cells whose productively rearranged H chain V region contained a VH81X gene segment were selectively disfavored both during pre-B cell development and subsequent to sIg expression. Contrary to the expectations for elimination by tolerance, no decrease in the proportion of cells expressing productive rearrangements of VH81X was observed as cells matured from the sIgMlow to the sIgMhigh maturational stage. However, a significant decrease in the proportion of productively rearranged VH81X gene segments was observed following the transition from sIg- pre-B cells to sIgMlow immature B cells. Additionally, the proportion of productively rearranged VH81X gene segments was significantly higher in sIgMhigh bone marrow cells than in splenic B cells. These findings demonstrate that B cells are susceptible to H chain-specific elimination at two developmental stages other than that wherein B cells are generally assumed to be negatively selected by tolerance.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7730605

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

Review 1.  Relative roles of somatic and Darwinian evolution in shaping the antibody response.

Authors:  M Diaz; N R Klinman
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

Review 2.  Development of B cells producing natural autoantibodies to thymocytes and senescent erythrocytes.

Authors:  Richard R Hardy; Kyoko Hayakawa
Journal:  Springer Semin Immunopathol       Date:  2004-12-21

Review 3.  Balancing immunity and tolerance: deleting and tuning lymphocyte repertoires.

Authors:  C C Goodnow
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-19       Impact factor: 11.205

4.  Selection of individual VH genes occurs at the pro-B to pre-B cell transition.

Authors:  Wenzhao Meng; Lenka Yunk; Li-San Wang; Avinash Maganty; Emily Xue; Philip L Cohen; Robert A Eisenberg; Martin G Weigert; Stephane J C Mancini; Eline T Luning Prak
Journal:  J Immunol       Date:  2011-07-11       Impact factor: 5.422

5.  Alternative mechanisms of receptor editing in autoreactive B cells.

Authors:  Olga Kalinina; Colleen M Doyle-Cooper; Jennifer Miksanek; Wenzhao Meng; Eline Luning Prak; Martin G Weigert
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-06       Impact factor: 11.205

Review 6.  Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies.

Authors:  Laurent Verkoczy; Garnett Kelsoe; M Anthony Moody; Barton F Haynes
Journal:  Curr Opin Immunol       Date:  2011-04-27       Impact factor: 7.486

7.  FoxO1 induces Ikaros splicing to promote immunoglobulin gene recombination.

Authors:  Alabbas Alkhatib; Markus Werner; Eva Hug; Sebastian Herzog; Cathrin Eschbach; Hemin Faraidun; Fabian Köhler; Thomas Wossning; Hassan Jumaa
Journal:  J Exp Med       Date:  2012-01-30       Impact factor: 14.307

8.  A novel mechanism for B cell repertoire maturation based on response by B cell precursors to pre-B receptor assembly.

Authors:  R Wasserman; Y S Li; S A Shinton; C E Carmack; T Manser; D L Wiest; K Hayakawa; R R Hardy
Journal:  J Exp Med       Date:  1998-01-19       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.